|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,651 GBX | +0.70% |
|
+2.51% | +13.85% |
| Apr. 23 | Edwards Lifesciences Corporation: The story continues |  |
| Apr. 22 | European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations | MT |
July 27 (Reuters) - GSK plc:
* GSK ANNOUNCES US FDA APPROVAL OF BENLYSTA (BELIMUMAB) FOR PEDIATRIC PATIENTS WITH ACTIVE LUPUS NEPHRITIS
* GSK - BENLYSTA IS NOW FIRST AND ONLY BIOLOGIC APPROVED FOR ADULTS AND CHILDREN WHO HAVE LUPUS OR LUPUS NEPHRITIS Source text for Eikon: Further company coverage:
| 1st Jan change | Capi. | |
|---|---|---|
| +13.85% | 82.63B | |
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
GSK PLC 
